Expresión inmunohistoquímica de PCNA, Ki-67 y ciclina D1 en ameloblastomas multiquísticos / Immunohistochemical expression of PCNA, Ki-67 and cyclin D1 in solid ameloblastomas

Introducción: el ameloblastoma es un tumor odontogénico benigno, localmente agresivo, que debe su origen a partir de estructuras epiteliales involucradas en la odontogénesis. El objetivo del presente trabajo es identificar, por medio de técnicas inmunohistoquímicas, aspectos de los mecanismos regulatorios de proliferación celular y la relación de los diferentes subtipos histológicos con el comportamiento biológico de estos tumores. Materiales y métodos: se seleccionaron 10 ameloblastomas multiquísticos en los cuales se realizó inmunotinción con los marcadores PCNA, Ki-67 y Ciclina D1. La interpretación de las tinciones se basó en la intensidad, localización y los subtipos celulares. La valoración utilizada para contabilizar el número de células fue baja (menos del 10 por ciento), media (hasta el 50 por ciento) y alta (más del 50 por ciento). Resultados: la tinción fue positiva en 6 casos para PCNA, en 3 para Ki-67 y en 5 para ciclina D1, en las células basales periféricas, en los patrones foliculares y plexiformes, en las del esbozo del retículo estrellado y fue negativa en los patrones quísticos y acantomatosos. Conclusión: en base a los hallazgos se puede asumir que las células basales y parabasales de los patrones foliculares y plexiformes presentan mayor actividad proliferativa que otros patrones y determinarían la evolución y tratamiento

Immunohistochemical Analysis of Nuclear Factor, p38, and Cyclin D1 Proteins in Premalignant Lesions and Carcinomas of the Colorectal Mucosa / 대한소화기학회지

BACKGROUND/AIMS: Nuclear factor-kappa B p65 (NF-kappa B p65), nuclear factor-kappa B1 p50 (NF-kappa B p50) have been shown to play a role in cell proliferation, apoptosis, cytokine production, and oncogenesis. Recently, p38 mitogen-activated protein kinase (MAPK)/ NF-kappa B/ cyclin D1 signaling pathway has been shown to play an important part in the pathogenesis of human cancers. This study was designed to investigate the expression of NF-kappa B p65, NF-kappa B p50, p38 MAPK alpha, and cyclin D1 proteins in premalignant lesions of colon and colorectal adenocarcinoma. METHODS: Paraffin sections of 20 normal mucosa, 20 low-grade tubular adenoma, 20 high-grade tubular adenoma and 64 adenocarcinoma tissues were analysed immunohistochemically for the expression of NF-kappa B p65, NF-kappa B p50, p38 MAPK alpha, and cyclin D1 proteins. RESULTS: The expression of NF-kappa B p65, NF-kappa B p50, and p38 MAPK alpha proteins were significantly higher in adenocarcinoma tissue in comparison with that in normal mucosa, low-grade tubular adenoma, and high-grade tubular adenoma tissues. Expression of NF-kappa B p50 was more frequent in poorly differentiated histologic grade, presence of nodal metastasis, and advanced stage. Expression of p38 MAPK alpha protein was higher in advanced tumor stage, presence of nodal metastasis and advanced stage. Synchronous expression of NF-kappa B p65, NF-kappa B p50, p38 MAPK alpha, and cyclin D1 proteins were significantly higher in adenocarcinoma tissue. CONCULSIONS: With the increased expression of NF-kappa B p65, NF-kappa B p50, and p38 MAPK alpha proteins, p38 MAPK/ NF-kappa B/ cyclin D1 signaling pathway may play a role in the pathogenesis of colorectal carcinoma.

Efficacy of Combination of Intravenous Cyclosporin A and Steroid Therapy versus Prolonged Intravenous Steroid Therapy Alone in Patients with Severe Ulcerative Colitis Refractory to Initial Intravenous Steroid Therapy / 대한소화기학회지

BACKGROUND/AIMS: Maximal duration of intravenous (IV) corticosteroid (CS) treatment and efficacy of cyclosporin A (CsA) have not been clarified for patients with severe ulcerative colitis. We aimed to evaluate and compare the effectiveness of CS and CsA combination therapy with prolonged CS therapy alone in patients with severe UC refractory to initial CS therapy. METHODS: We retrospectively reviewed the medical records of 84 episodes of severe UC in 59 patients between April 1999 and May 2005. RESULTS: Among 84 episodes with IV CS therapy, 45 (53.6%) experienced an early response, while 39 (46.4%) did not respond within 2 weeks. The remaining 36 episodes excluding 3 which underwent colectomy were assigned to either combination therapy of IV CS and CsA or prolonged IV CS treatment alone for additional 2 weeks. Twelve of 16 episodes (75.0%) responded to therapy with combinations of IV CsA and CS, and 16 of 20 episodes (80.0%) to prolonged IV CS treatment alone. There was no statistical difference in response and colectomy rate after 4 weeks between CsA-use group and CsA-non-use group (p=1.00). CONCLUSIONS: These results suggest that CS and CsA combination has no additional benefit over prolonged CS therapy alone in terms of short-term response and that CS can be safely prolonged even after the first 14 days of treatment for severe UC.